<DOC>
	<DOCNO>NCT01246206</DOCNO>
	<brief_summary>The primary goal study determine incidence severity acute Graft versus Host Disease ( GVHD ) follow human leukocyte antigen ( HLA ) match related donor Hematopoetic Stem Cell ( HSC ) transplant patient blood relate cancer receive combination tacrolimus Thymoglobulin GVHD prophylaxis . The investigator also determine safety combination first six month post transplant . Secondary goal include determine time recovery white blood cell platelet ( engraftment ) , determine occurrence opportunistic infection , define infection occur people weaken immune system cause organisms normally cause disease ( fungal infection , pneumocystis carinii pneumonia ( PCP ) , viral infection ) , estimate incidence chronic GVHD two year overall disease free survival two year . Immune response assess mean immuno-correlative study prior various point transplant .</brief_summary>
	<brief_title>Tacrolimus Thymoglobulin , GvHD Prophylaxis Patients Undergoing Related Donor HCT</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Suitable relate donor determine treat physician High resolution molecular HLA type mandatory HLA Class I II Diagnosis hematological malignancy Patients one follow hematologic malignancy , felt transplant candidate treat physician eligible enroll protocol : NonHodgkin lymphoma , complete remission ( CR ) /partial remission ( PR ) Hodgkin disease , CR/PR/stable disease ( SD ) Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) CR ; nonCR AML ALL , bone marrow blast &lt; 20 % within 4 week transplant peripheral blood ( PB ) absolute blast count &lt; 500/μl day initiation condition Myelodysplastic syndrome ( MDS ) , treat untreated Chronic myelogenous leukemia ( CML ) chronic phase accelerate phase Chronic myelomonocytic leukemia ( CMML ) Multiple myeloma , CR/PR/SD Chronic lymphocytic leukemia ( CLL ) CR/PR Myelofibrosis myeloproliferative disorder ; bone marrow blast less 20 percent within four week transplant peripheral blood absolute blast count less 500 per microliter day initiation condition Age &gt; = 18 able cooperate oral medication intake Filgrastim ( GCSF ) mobilize Peripheral blood stem cell Agrees participate , informed consent sign Karnofsky performance status ( KPS ) &gt; = 60 , Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Creatinine clearance &gt; 60 mL/min Ejection fraction &gt; 50 % Serum bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less 3 X upper limit normal Forced vital capacity ( FVC ) , forced expiratory volume one second ( FEV1 ) diffusion capacity carbon monoxide ( DLCO ) &gt; 50 % predict Bone marrow Ex vivo engineer process graft ( cluster differentiation [ CD ] 34+ enrichment , Tcell depletion , etc ) Patients document uncontrolled central nervous system ( CNS ) disease Active donor recipient serology positive human immunodeficiency virus ( HIV ) Known contraindication administration Tacrolimus Thymoglobulin Active Hepatitis B C Patients coronary heart disease ( recent myocardial infarction , angina , cardiac stent , bypass surgery last 6 month ) need clear stress echocardiogram nuclear myocardial perfusion stress test , cardiology consult ; cardiac history discretion Principal Investigator Oxygen usage time enrollment Patients clinical ascites Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>● Non-Hodgkin lymphoma ,</keyword>
	<keyword>● Hodgkin disease ,</keyword>
	<keyword>● Acute Myelogenous Acute Lymphocytic Leukemia</keyword>
	<keyword>● Myelodysplastic Syndromes ,</keyword>
	<keyword>● Chronic Myelogenous Leukemia</keyword>
	<keyword>● Multiple Myeloma</keyword>
	<keyword>● Chronic Lymphocytic Leukemia</keyword>
	<keyword>● Myelofibrosis myeloproliferative disorder ;</keyword>
</DOC>